Leonard S Marks

Title(s)Professor-in-Residence, Urology
SchoolMedicine
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Focal Laser Ablation of Prostate Cancer using MR/US Fusion
    NIH R01CA218547Jun 19, 2017 - May 31, 2022
    Role: Principal Investigator
    Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer
    NIH R01CA195505May 19, 2015 - Apr 30, 2018
    Role: Principal Investigator
    Biopsy Tracking and MRI Fusion to Enhance Imaging of Cancer Within the Prostate
    NIH R01CA158627Jul 5, 2011 - Jun 30, 2014
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A prostate cancer risk calculator (PCRC-MRI): Use of clinical and magnetic resonance imaging data to predict biopsy outcome in North American men. Can Urol Assoc J. 2021 Oct 18. Kinnaird A, Brisbane W, Kwan L, Priester A, Chuang R, Barsa DE, Delfin M, Sisk A, Margolis D, Felker E, Hu J, Marks LS. PMID: 34672937.
      View in: PubMed   Mentions:
    2. Editorial Comment. J Urol. 2021 Oct 11; 101097JU000000000000218201. Marks LS, Brisbane WG. PMID: 34633211.
      View in: PubMed   Mentions:    Fields:    
    3. Editorial Comment. J Urol. 2021 Oct 04; 101097JU000000000000212001. Marks LS, Brisbane WG, Priester AM. PMID: 34601895.
      View in: PubMed   Mentions:    Fields:    
    4. Textured-Based Deep Learning in Prostate Cancer Classification with 3T Multiparametric MRI: Comparison with PI-RADS-Based Classification. Diagnostics (Basel). 2021 Sep 28; 11(10). Liu Y, Zheng H, Liang Z, Miao Q, Brisbane WG, Marks LS, Raman SS, Reiter RE, Yang G, Sung K. PMID: 34679484; PMCID: PMC8535024.
      View in: PubMed   Mentions:
    5. Reply by Authors. J Urol. 2021 Nov; 206(5):1156. Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg SL, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ. PMID: 34503354.
      View in: PubMed   Mentions:    Fields:    
    6. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. J Urol. 2021 Nov; 206(5):1147-1156. Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg SL, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ. PMID: 34503355.
      View in: PubMed   Mentions:    Fields:    
    7. Federated learning improves site performance in multicenter deep learning without data sharing. J Am Med Inform Assoc. 2021 06 12; 28(6):1259-1264. Sarma KV, Harmon S, Sanford T, Roth HR, Xu Z, Tetreault J, Xu D, Flores MG, Raman AG, Kulkarni R, Wood BJ, Choyke PL, Priester AM, Marks LS, Raman SS, Enzmann D, Turkbey B, Speier W, Arnold CW. PMID: 33537772.
      View in: PubMed   Mentions: 1     Fields:    
    8. Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer. J Urol. 2021 09; 206(3):595-603. Raman AG, Sarma KV, Raman SS, Priester AM, Mirak SA, Riskin-Jones HH, Dhinagar N, Speier W, Felker E, Sisk AE, Lu D, Kinnaird A, Reiter RE, Marks LS, Arnold CW. PMID: 33908801.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Focal Laser Ablation of Prostate Cancer: An Office Procedure. J Vis Exp. 2021 03 30; (169). Brisbane WG, Natarajan S, Priester A, Felker ER, Kinnaird A, Marks LS. PMID: 33871450.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. Urol Oncol. 2021 Mar 03. Tan WP, Rastinehad AR, Klotz L, Carroll PR, Emberton M, Feller JF, George AK, Gill IS, Gupta RT, Katz AE, Lebastchi AH, Marks LS, Marra G, Pinto PA, Song DY, Sidana A, Ward JF, Sanchez-Salas R, Rosette J, Polascik TJ, Focal Therapy Consensus group. PMID: 33676851.
      View in: PubMed   Mentions:    Fields:    
    11. Editorial Comment. J Urol. 2021 03; 205(3):798. Marks LS, Brisbane WG. PMID: 33393830.
      View in: PubMed   Mentions:    Fields:    
    12. Semi-automated PIRADS scoring via mpMRI analysis. J Med Imaging (Bellingham). 2020 Nov; 7(6):064501. Dhinagar NJ, Speier W, Sarma KV, Raman A, Kinnaird A, Raman SS, Marks LS, Arnold CW. PMID: 33392358.
      View in: PubMed   Mentions:
    13. Hemigland Cryoablation of Clinically Significant Prostate Cancer: Intermediate-Term Followup via Magnetic Resonance Imaging Guided Biopsy. J Urol. 2020 Nov; 204(5):941-949. Chuang R, Kinnaird A, Kwan L, Sisk A, Barsa D, Felker E, Delfin M, Marks L. PMID: 32985924.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Moving away from systematic biopsies: image-guided prostate biopsy (in-bore biopsy, cognitive fusion biopsy, MRUS fusion biopsy) -literature review. World J Urol. 2021 Mar; 39(3):677-686. Yamada Y, Ukimura O, Kaneko M, Matsugasumi T, Fujihara A, Vourganti S, Marks L, Sidana A, Klotz L, Salomon G, de la Rosette J. PMID: 32728885.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. Eur Urol. 2021 04; 79(4):456-465. Salami SS, Tosoian JJ, Nallandhighal S, Jones TA, Brockman S, Elkhoury FF, Bazzi S, Plouffe KR, Siddiqui J, Liu CJ, Kunju LP, Morgan TM, Natarajan S, Boonstra PS, Sumida L, Tomlins SA, Udager AM, Sisk AE, Marks LS, Palapattu GS. PMID: 32631746.
      View in: PubMed   Mentions: 1     Fields:    
    16. Risk of Prostate Cancer after a Negative Magnetic Resonance Imaging Guided Biopsy. J Urol. 2020 12; 204(6):1180-1186. Kinnaird A, Sharma V, Chuang R, Priester A, Tran E, Barsa DE, Delfin M, Kwan L, Sisk A, Felker E, Marks LS. PMID: 32614257.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Monitoring Focal Laser Ablation with Interstitial Fluence Probes: Monte Carlo Simulation and Phantom Validation. Annu Int Conf IEEE Eng Med Biol Soc. 2020 07; 2020:5272-5275. Geoghegan R, Priester A, Zhang L, Wu H, Marks L, Natarajan S. PMID: 33019173.
      View in: PubMed   Mentions:
    18. Value of systematic sampling in an mp-MRI targeted prostate biopsy strategy. Transl Androl Urol. 2020 Jun; 9(3):1501-1509. Connor MJ, Miah S, Jayadevan R, Khoo CC, Eldred-Evans D, Shah T, Ahmed HU, Marks L. PMID: 32676437.
      View in: PubMed   Mentions: 1  
    19. Prostate Cancer Detection Rate of Freehand versus 3-Dimensional Template Mapping Biopsy Using a Magnetic Resonance Imaging-Ultrasound Fusion Device in Biopsy Naïve Men. Letter. J Urol. 2021 06; 205(6):1843. Marks LS, Natarajan S. PMID: 32364836.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions. Urol Oncol. 2020 07; 38(7):637.e9-637.e15. Al Hussein Al Awamlh B, Marks LS, Sonn GA, Natarajan S, Fan RE, Gross MD, Mauer E, Banerjee S, Hectors S, Carlsson S, Margolis DJ, Hu JC. PMID: 32307327.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    21. Editorial Comment. J Urol. 2020 05; 203(5):924. Marks LS, Kinnaird A. PMID: 32077800.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. An Electronic Form for Reporting Results of Targeted Prostate Biopsy: Urology Integrated Diagnostic Report (Uro-IDR). Urology. 2020 Apr; 138:188-193. Guorgui J, Kinnaird A, Jayadevan R, Priester AM, Arnold CW, Marks LS. PMID: 31978527.
      View in: PubMed   Mentions:    Fields:    
    23. Using spatial tracking with magnetic resonance imaging/ultrasound-guided biopsy to identify unilateral prostate cancer. BJU Int. 2020 03; 125(3):399-406. Zhou SR, Priester AM, Jayadevan R, Johnson DC, Yang JJ, Ballon J, Natarajan S, Marks LS. PMID: 31680423.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Editorial Comment. J Urol. 2020 01; 203(1):106-107. Kinnaird A, Marks LS. PMID: 31618155.
      View in: PubMed   Mentions:    Fields:    
    25. Prostate Cancer Detection Rate of Freehand versus 3-Dimensional Template Mapping Biopsy Using a Magnetic Resonance Imaging-Ultrasound Fusion Device in Biopsy Naïve Men. J Urol. 2020 04; 203(4):699-705. Zhou SR, Chang E, Patankar A, Huang J, Marks LS, Natarajan S. PMID: 31596671.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    26. Variation in Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Outcomes in Asian American Men: A Multicenter Study. J Urol. 2020 03; 203(3):530-536. Gross MD, Marks LS, Sonn GA, Green DA, Wang GJ, Shoag JE, Cabezon E, Margolis DJ, Robinson BD, Hu JC. PMID: 31502942.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    27. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer. JAMA Netw Open. 2019 09 04; 2(9):e1911019. Jayadevan R, Felker ER, Kwan L, Barsa DE, Zhang H, Sisk AE, Delfin M, Marks LS. PMID: 31509206.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    28. Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study. JAMA Surg. 2019 09 01; 154(9):811-818. Elkhoury FF, Felker ER, Kwan L, Sisk AE, Delfin M, Natarajan S, Marks LS. PMID: 31188412.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    29. Utility of Multiparametric MRI for Predicting Residual Clinically Significant Prostate Cancer After Focal Laser Ablation. AJR Am J Roentgenol. 2019 12; 213(6):1253-1258. Felker ER, Raman SS, Lu DSK, Tuttle M, Margolis DJ, ElKhoury FF, Sayre J, Marks LS. PMID: 31361529.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection. Cancer. 2019 09 01; 125(17):2955-2964. Johnson DC, Yang JJ, Kwan L, Barsa DE, Mirak SA, Pooli A, Sadun T, Jayadevan R, Zhou S, Priester AM, Natarajan S, Bajgiran AM, Shakeri S, Sisk A, Felker ER, Raman SS, Marks LS, Reiter RE. PMID: 31042322.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    31. Utility of Restriction Spectrum Imaging Among Men Undergoing First-Time Biopsy for Suspected Prostate Cancer. AJR Am J Roentgenol. 2019 08; 213(2):365-370. Felker ER, Raman SS, Shakeri S, Mirak SA, Bajgiran AM, Kwan L, Khoshnoodi P, ElKhoury FF, Margolis DJA, Karow D, Lu DSK, White N, Marks LS. PMID: 31039011.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    32. Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy. J Vis Exp. 2019 04 09; (146). Jayadevan R, Zhou S, Priester AM, Delfin M, Marks LS. PMID: 31033955.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    33. Cancer core length from targeted biopsy: an index of prostate cancer volume and pathological stage. BJU Int. 2019 08; 124(2):275-281. Simopoulos DN, Sisk AE, Priester A, Felker ER, Kwan L, Delfin MK, Reiter RE, Marks LS. PMID: 30694605.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    34. Use of MRI-Guided Biopsy for Selection and Follow-up of Men Undergoing Hemi-gland Cryoablation of Prostate Cancer. Urology. 2019 04; 126:158-164. Zhou SR, Simopoulos DN, Jayadevan R, Felker ER, Delfin MK, Barsa DE, Kwan L, Marks LS. PMID: 30659903.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. Exclusive MRI-targeted biopsy: not so fast. Lancet Oncol. 2019 01; 20(1):9-10. Jayadevan R, Marks LS. PMID: 30470503.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Editorial Comment. J Urol. 2018 12; 200(6):1240. Marks LS. PMID: 30172886.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    37. Radical prostatectomy then and now: Surgical overtreatment of prostate cancer is declining from 2009 to 2016 at a tertiary referral center. Urol Oncol. 2018 09; 36(9):401.e19-401.e25. Salmasi A, Faiena I, Wu J, Sisk AE, Sachveda A, Vandel JJ, Chamie K, Marks LS, Reiter RE. PMID: 30064933.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. Editorial Comment. J Urol. 2018 09; 200(3):563. Marks LS. PMID: 29913157.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Targeted Prostate Biopsy Gleason Score Heterogeneity and Implications for Risk Stratification. Am J Clin Oncol. 2018 05; 41(5):497-501. Mesko S, Marks L, Ragab O, Patel S, Margolis DA, Demanes DJ, Kamrava M. PMID: 27281263.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    40. Registration Accuracy of Patient-Specific, Three-Dimensional-Printed Prostate Molds for Correlating Pathology With Magnetic Resonance Imaging. IEEE Trans Biomed Eng. 2019 01; 66(1):14-22. Priester A, Wu H, Khoshnoodi P, Schneider D, Zhang Z, Asvadi NH, Sisk A, Raman S, Reiter R, Grundfest W, Marks LS, Natarajan S. PMID: 29993431.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy. J Urol. 2018 09; 200(3):564-572. Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk AE, Grogan T, McCullough D, Bennett J, Bailey H, Lawrence HJ, Elashoff DA, Marks LS, Raman SS, Febbo PG, Reiter RE. PMID: 29524506.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    42. MR-guided biopsy and focal therapy: new options for prostate cancer management. Curr Opin Urol. 2018 03; 28(2):93-101. Elkhoury FF, Simopoulos DN, Marks LS. PMID: 29232269.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    43. Editorial Comment. J Urol. 2018 04; 199(4):981-982. Marks LS. PMID: 29360445.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    44. Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies. J Urol. 2018 06; 199(6):1488-1493. Golan R, Bernstein A, Sedrakyan A, Daskivich TJ, Du DT, Ehdaie B, Fisher B, Gorin MA, Grunberger I, Hunt B, Jiang HH, Kim HL, Marinac-Dabic D, Marks LS, McClure TD, Montgomery JS, Parekh DJ, Punnen S, Scionti S, Viviano CJ, Wei JT, Wenske S, Wysock JS, Rewcastle J, Carol M, Oczachowski M, Hu JC. PMID: 29307684.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    45. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2018 03; 59(3):434-441. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. PMID: 29242398.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    46. Targeted Prostate Biopsy in the Era of Active Surveillance. Urology. 2018 Feb; 112:12-19. Elkhoury FF, Simopoulos DN, Marks LS. PMID: 28962878.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    47. Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary? AJR Am J Roentgenol. 2017 Dec; 209(6):1272-1277. Felker ER, Raman SS, Margolis DJ, Lu DSK, Shaheen N, Natarajan S, Sharma D, Huang J, Dorey F, Marks LS. PMID: 28858541.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    48. Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy. J Urol. 2018 02; 199(2):453-458. Nassiri N, Chang E, Lieu P, Priester AM, Margolis DJA, Huang J, Reiter RE, Dorey FJ, Marks LS, Natarajan S. PMID: 28830754.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    49. Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer. J Urol. 2018 01; 199(1):98-105. Chang E, Jones TA, Natarajan S, Sharma D, Simopoulos D, Margolis DJ, Huang J, Dorey FJ, Marks LS. PMID: 28728993.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    50. High Intensity Focused Ultrasound for Radiorecurrent Prostate Cancer: A North American Clinical Trial. J Urol. 2018 01; 199(1):133-139. Jones TA, Chin J, Mcleod D, Barkin J, Pantuck A, Marks LS. PMID: 28652121.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    51. Targeted Prostate Biopsy Using 68Gallium PSMA-PET/CT for Image Guidance. Urol Case Rep. 2017 Sep; 14:11-14. Simopoulos DN, Natarajan S, Jones TA, Fendler WP, Sisk AE, Marks LS. PMID: 28607878.
      View in: PubMed   Mentions: 7  
    52. Focal Laser Ablation of Prostate Cancer: Feasibility of Magnetic Resonance Imaging-Ultrasound Fusion for Guidance. J Urol. 2017 10; 198(4):839-847. Natarajan S, Jones TA, Priester AM, Geoghegan R, Lieu P, Delfin M, Felker E, Margolis DJA, Sisk A, Pantuck A, Grundfest W, Marks LS. PMID: 28396184.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    53. The First Filmed Prostatectomy, 1917: 100 Years of Movies in Urological Education. Urology. 2017 Jul; 105:29-32. Huen KH, Nseyo U, Marks LS. PMID: 28363740.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. Re: A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population. Eur Urol. 2017 06; 71(6):986-987. Jones TA, Marks LS. PMID: 28233592.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    55. Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy. Abdom Radiol (NY). 2017 Feb; 42(2):346-349. Verma S, Rosenkrantz AB, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, Marks LS, Pinto P, Sonn GA, Taneja SS. PMID: 27670878.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    56. Editorial Comment. Urology. 2017 04; 102:195-196. Marks LS. PMID: 28034528.
      View in: PubMed   Mentions:    Fields:    
    57. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer. Brachytherapy. 2017 Mar - Apr; 16(2):299-305. Patel S, Demanes DJ, Ragab O, Zhang M, Veruttipong D, Nguyen K, Park SJ, Marks L, Pantuck A, Steinberg M, Kamrava M. PMID: 27965117.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    58. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU Int. 2017 07; 120(1):61-68. Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ. PMID: 27743489.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    59. Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer. Clin Cancer Res. 2017 Feb 15; 23(4):985-991. Palapattu GS, Salami SS, Cani AK, Hovelson DH, Lazo de la Vega L, Vandenberg KR, Bratley JV, Liu CJ, Kunju LP, Montgomery JS, Morgan TM, Natarajan S, Huang J, Tomlins SA, Marks LS. PMID: 28031426.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    60. Focal Laser Ablation of Prostate Cancer. Urology. 2017 Jan; 99:e21-e22. Jones TA, Natarajan S, Priester AM, Marks LS. PMID: 27720973.
      View in: PubMed   Mentions: 1     Fields:    
    61. Some prostate cancers are invisible to magnetic resonance imaging! BJU Int. 2016 10; 118(4):492-3. Marks LS. PMID: 27625328.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    62. Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer. J Urol. 2017 03; 197(3 Pt 1):632-639. Nassiri N, Margolis DJ, Natarajan S, Sharma DS, Huang J, Dorey FJ, Marks LS. PMID: 27639713.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    63. Optimizing safety and accuracy of prostate biopsy. Curr Opin Urol. 2016 09; 26(5):472-80. Jones TA, Radtke JP, Hadaschik B, Marks LS. PMID: 27214580.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    64. Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. J Urol. 2017 02; 197(2):320-326. Hanna RF, Ward TJ, Chow DS, Lagana SM, Moreira RK, Emond JC, Weintraub JL, Prince MR, Priester A, Natarajan S, Khoshnoodi P, Margolis DJ, Raman SS, Reiter RE, Huang J, Grundfest W, Marks LS. PMID: 27484386; PMCID: PMC5540646.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    65. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016 12; 196(6):1613-1618. Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, Marks LS, Pinto P, Sonn GA, Taneja SS. PMID: 27320841.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    66. Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. J Urol. 2016 Oct; 196(4):1096-104. Taneja SS, Bennett J, Coleman J, Grubb R, Andriole G, Reiter RE, Marks L, Azzouzi AR, Emberton M. PMID: 27291652.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    67. Prostate cancer risk stratification with magnetic resonance imaging. Urol Oncol. 2016 07; 34(7):311-9. Felker ER, Margolis DJ, Nassiri N, Marks LS. PMID: 27040381.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    68. The Relationship between Intolerance of Uncertainty and Anxiety in Men on Active Surveillance for Prostate Cancer. J Urol. 2016 06; 195(6):1724-30. Tan HJ, Marks LS, Hoyt MA, Kwan L, Filson CP, Macairan M, Lieu P, Litwin MS, Stanton AL. PMID: 26872841.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    69. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer. 2016 Mar 15; 122(6):884-92. Filson CP, Natarajan S, Margolis DJ, Huang J, Lieu P, Dorey FJ, Reiter RE, Marks LS. PMID: 26749141.
      View in: PubMed   Mentions: 95     Fields:    Translation:Humans
    70. Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial. J Urol. 2016 07; 196(1):68-75. Natarajan S, Raman S, Priester AM, Garritano J, Margolis DJ, Lieu P, Macairan ML, Huang J, Grundfest W, Marks LS. PMID: 26748164.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    71. Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value. J Urol. 2016 May; 195(5):1421-1427. Felker ER, Wu J, Natarajan S, Margolis DJ, Raman SS, Huang J, Dorey F, Marks LS. PMID: 26674305.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    72. Targeted prostate biopsy using magnetic resonance imaging-ultrasound fusion. Asian J Androl. 2015 Nov-Dec; 17(6):870-3. Bockholt N, Marks LS. PMID: 26289396.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    73. Prostate diffusion imaging with distortion correction. Magn Reson Imaging. 2015 Nov; 33(9):1178-1181. Rakow-Penner RA, White NS, Margolis DJA, Parsons JK, Schenker-Ahmed N, Kuperman JM, Bartsch H, Choi HW, Bradley WG, Shabaik A, Huang J, Liss MA, Marks L, Kane CJ, Reiter RE, Raman SS, Karow DS, Dale AM. PMID: 26220859.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    74. Targeted Prostate Biopsy: Lessons Learned Midst the Evolution of a Disruptive Technology. Urology. 2015 Sep; 86(3):432-8. Nassiri N, Natarajan S, Margolis DJ, Marks LS. PMID: 26166671.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    75. Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. Pract Radiat Oncol. 2015 Nov-Dec; 5(6):411-6. Kamrava M, Kishan AU, Margolis DJ, Huang J, Dorey F, Lieu P, Kupelian PA, Marks LS. PMID: 26059510.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    76. Expectant management for men with early stage prostate cancer. CA Cancer J Clin. 2015 Jul-Aug; 65(4):265-82. Filson CP, Marks LS, Litwin MS. PMID: 25958817.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    77. Does the addition of targeted prostate biopsies to standard systemic biopsies influence treatment management for radiation oncologists? BJU Int. 2016 Apr; 117(4):584-91. Kamrava M, Hegde JV, Abgaryan N, Chang E, Le JD, Wang J, Kupelian PA, Marks LS. PMID: 25684394.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    78. Significance of Change in Gleason Grade in Patients on Active Surveillance for Prostate Cancer. J Urol. 2015 Jul; 194(1):8-9. Marks LS. PMID: 25892137.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    79. Joseph J. Kaufman: renaissance man. Urology. 2015 Mar; 85(3):487-90. Kaplan AL, Ehrlich RM, Marks LS, Walsh PC, Bloom DA, Hu JC. PMID: 25733256.
      View in: PubMed   Mentions:    Fields:    
    80. MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens. Front Oncol. 2015; 5:30. Liss MA, White NS, Parsons JK, Schenker-Ahmed NM, Rakow-Penner R, Kuperman JM, Bartsch H, Choi HW, Mattrey RF, Bradley WG, Shabaik A, Huang J, Margolis DJ, Raman SS, Marks LS, Kane CJ, Reiter RE, Dale AM, Karow DS. PMID: 25741473.
      View in: PubMed   Mentions: 5  
    81. Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. Eur Urol. 2015 Jul; 68(1):8-19. Valerio M, Donaldson I, Emberton M, Ehdaie B, Hadaschik BA, Marks LS, Mozer P, Rastinehad AR, Ahmed HU. PMID: 25454618.
      View in: PubMed   Mentions: 108     Fields:    Translation:Humans
    82. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol. 2015 Mar; 67(3):569-76. Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS, Huang J, Margolis DJ, Raman SS, Reiter RE. PMID: 25257029.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    83. A system for evaluating magnetic resonance imaging of prostate cancer using patient-specific 3D printed molds. Am J Clin Exp Urol. 2014; 2(2):127-35. Priester A, Natarajan S, Le JD, Garritano J, Radosavcev B, Grundfest W, Margolis DJ, Marks LS, Huang J. PMID: 25374914.
      View in: PubMed   Mentions: 16  
    84. Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer. Urol Oncol. 2014 Oct; 32(7):952-7. Sonn GA, Filson CP, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ, Reiter RE, Marks LS. PMID: 25027689.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    85. Targeted prostate biopsy: value of multiparametric magnetic resonance imaging in detection of localized cancer. Asian J Androl. 2014 Jul-Aug; 16(4):522-9. Le JD, Huang J, Marks LS. PMID: 24589455.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    86. Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. J Urol. 2014 Nov; 192(5):1367-73. Le JD, Stephenson S, Brugger M, Lu DY, Lieu P, Sonn GA, Natarajan S, Dorey FJ, Huang J, Margolis DJ, Reiter RE, Marks LS. PMID: 24793118.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    87. Screening and detection advances in magnetic resonance image-guided prostate biopsy. Urol Clin North Am. 2014 May; 41(2):315-26. Stephenson SK, Chang EK, Marks LS. PMID: 24725492.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    88. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol. 2014 Oct; 192(4):1081-7. Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, Trock BJ, Lance RS, Bigley JW, Van Criekinge W, Epstein JI. PMID: 24747657.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCellsCTClinical Trials
    89. Improving risk stratification in patients with prostate cancer managed by active surveillance: nomogram predicting the risk of biopsy progression. BJU Int. 2014 Apr; 113(4):E13-4. Marks LS. PMID: 24629086.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    90. Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply? J Urol. 2014 Aug; 192(2):385-90. Hu JC, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Sonn G, Dorey FJ, Marks LS. PMID: 24512956.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    91. Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. Urol Oncol. 2014 Aug; 32(6):903-11. Sonn GA, Margolis DJ, Marks LS. PMID: 24239473.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    92. MRI before prostate biopsy--yes or no? J Urol. 2013 Dec; 190(6):1978-80. Albertsen PC, Marks LS. PMID: 23994537.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    93. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013 Oct; 64(4):544-52. Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Fütterer JJ, Gill IS, Grubb Iii RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y, START Consortium . PMID: 23537686.
      View in: PubMed   Mentions: 106     Fields:    Translation:Humans
    94. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol. 2014 Apr; 65(4):809-15. Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ, Reiter RE, Marks LS. PMID: 23523537.
      View in: PubMed   Mentions: 132     Fields:    Translation:Humans
    95. Focal high-dose-rate brachytherapy: a dosimetric comparison of hemigland vs. conventional whole-gland treatment. Brachytherapy. 2013 Sep-Oct; 12(5):434-41. Kamrava M, Chung MP, Kayode O, Wang J, Marks L, Kupelian P, Steinberg M, Park SJ, Demanes DJ. PMID: 23406987.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    96. Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2013 Jan; 189(1 Suppl):S122-8. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. PMID: 23234617.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    97. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol. 2013 Jan; 23(1):43-50. Marks L, Young S, Natarajan S. PMID: 23138468.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    98. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol. 2013 Jan; 189(1):86-91. Sonn GA, Natarajan S, Margolis DJ, MacAiran M, Lieu P, Huang J, Dorey FJ, Marks LS. PMID: 23158413.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    99. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol. 2013 Feb; 63(2):201-9. Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Fisch M, Abbou CC, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Pummer K, Graefen M, Haese A, Walz J, Briganti A, Shariat SF, Chun FK. PMID: 22854248.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    100. Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol. 2011 May-Jun; 29(3):334-42. Natarajan S, Marks LS, Margolis DJ, Huang J, Macairan ML, Lieu P, Fenster A. PMID: 21555104.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    101. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med. 2011 Apr 19; 9:43. Xie C, Kim HJ, Haw JG, Kalbasi A, Gardner BK, Li G, Rao J, Chia D, Liong M, Punzalan RR, Marks LS, Pantuck AJ, de la Taille A, Wang G, Mukouyama H, Zeng G. PMID: 21504557.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    102. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011 May; 185(5):1650-5. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA. PMID: 21419439.
      View in: PubMed   Mentions: 142     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    103. Words of wisdom. Re: copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Eur Urol. 2010 Apr; 57(4):727-8. Marks LS, Huang J. PMID: 20965042.
      View in: PubMed   Mentions:    Fields:    
    104. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology. 2009 Dec; 74(6):1318-22. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. PMID: 19815265.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    105. Should testosterone replacement be given to men with large prostates? J Urol. 2009 Nov; 182(5):2109-11. Marks LS, Kaplan SA. PMID: 19758636.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    106. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009 Jun; 181(6):2634-40. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. PMID: 19371887.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    107. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol. 2009 Jul; 56(1):48-56. Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C. PMID: 19375844.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    108. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol. 2009 Oct; 56(4):659-67. Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Stillebroer AB, van Gils MP, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Haese A. PMID: 19304372.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    109. Words of wisdom. Re: Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Eur Urol. 2009 Mar; 55(3):750-1. Marks LS. PMID: 19650234.
      View in: PubMed   Mentions:    Fields:    
    110. Prostate tissue androgens: history and current clinical relevance. Urology. 2008 Aug; 72(2):247-54. Marks LS, Mostaghel EA, Nelson PS. PMID: 18502483.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    111. Editorial comment. J Urol. 2008 May; 179(5):1744-5. Marks LS. PMID: 18343450.
      View in: PubMed   Mentions:    Fields:    
    112. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008 Apr; 179(4):1587-92. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J. PMID: 18295257.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCTClinical Trials
    113. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response. J Urol. 2007 Apr; 177(4):1408-13. Marks LS, Roehrborn CG, Wolford E, Wilson TH. PMID: 17382742.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    114. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007 Mar; 69(3):532-5. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J. PMID: 17382159.
      View in: PubMed   Mentions: 113     Fields:    Translation:Humans
    115. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006 Nov 15; 296(19):2351-61. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS. PMID: 17105798.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCells
    116. Prevention of benign prostatic hyperplasia disease. J Urol. 2006 Oct; 176(4 Pt 1):1299-306. Marks LS, Roehrborn CG, Andriole GL. PMID: 16952616.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    117. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol. 2006 Sep; 176(3):868-74. Hanna RF, Ward TJ, Chow DS, Lagana SM, Moreira RK, Emond JC, Weintraub JL, Prince MR, Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. PMID: 16890642.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    118. Prostatic tissue testosterone and dihydrotestosterone in African-American and white men. Urology. 2006 Aug; 68(2):337-41. Marks LS, Hess DL, Dorey FJ, Macairan ML. PMID: 16904448.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    119. Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease. Curr Urol Rep. 2006 Jul; 7(4):293-303. Marks LS. PMID: 16930501.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    120. Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue. Urology. 2004 Oct; 64(4):765-71. Marks LS, Kojima M, Demarzo A, Heber D, Bostwick DG, Qian J, Dorey FJ, Veltri RW, Mohler JL, Partin AW. PMID: 15491717.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    121. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004 Apr; 63(4):709-15. Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morrill B, Wolford ET. PMID: 15072886.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    122. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. Urology. 2003 Nov; 62(5):888-93. Marks LS, Roehrborn CG, Gittelman M, Kim D, Forrest J, Jacobs S. PMID: 14624914.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    Leonard's Networks
    Concepts (233)
    Derived automatically from this person's publications.
    _
    Co-Authors (43)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _